Millions of
eczema patients underserved by topical steroid creams are expected to drive annual Dupixent sales past the $ 4 billion mark for partners Sanofi (NYSE: SNY) and Regeneron (NASDAQ: REGN), but it looks as if ANB020 will provide fierce competition.